ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO544

Real Time Utilization of TIMP2*IGFBP7 in ICU Patients: A Quality Initiative

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Koyner, Jay L., University of Chicago, Chicago, Illinois, United States
  • Gunning, Samantha, University of Chicago, Chicago, Illinois, United States
  • Kunczt, Alissa, University of Chicago, Chicago, Illinois, United States
  • Trevino, Sharon A., University of Chicago, Chicago, Illinois, United States
  • Chan, Siaw li, Rochester Regional Health, Rochester, New York, United States
  • Groboske, Sarah E., University of Chicago, Chicago, Illinois, United States
  • Leung, Edward Ki yun, The University of Chicago, Chicago, Illinois, United States
  • Yeo, Kiang-Teck Jerry, University of Chicago, Chicago, Illinois, United States
Background

Little is known about the real-time clinical use of urinary [tissue inhibitor of metalloproteinase-2]*[insulin-like growth factor binding protein 7] (Nephrocheck, Astute Medical) (NC) in mixed ICU patients at risk for acute kidney injury (AKI).

Methods

We conducted a single center before and after quality initiative assessing outcomes in ICU patients at risk for severe AKI (defined as elevated cardiovascular or pulmonary SOFA score or having KDIGO Stage 1 AKI). We compared 70 retrospective patients who had NC measured but never clinically reported with 60 prospective patients who had NC reported with clinical guidance about their severe AKI risk. We assessed patient outcomes including maximal AKI stage, need for RRT, nephrotoxin exposure and need for nephrology consult.

Results

There was no difference in age, race, gender, baseline hypertension, diabetes, CKD, baseline serum creatinine (SCr) between the retrospective and prospective cohorts. Compared to prospective patients, retrospective patients had higher APACHE II scores(p<0.001), but there was no difference in the need for vasoactive medications(p=0.87). On the day the biomarker was measured both SCr and NC were higher in the prospective cohort.(Table) Despite higher NC values in the prospective cohort there was no difference in the development of Stage 2/3 AKI (p=0.72) or the need for RRT (p=0.68). There was a trend toward decreased mortality in the prospective group (p=0.08). The prospective cohort was more likely to have a nephrology consult in the 24 hours following NC measurement. Prospective patients with a NC>2.0 (n=19) were less likely to be exposed to a nephrotoxins (NSAIDs, Aminoglycosides, amphotericin,r adiocontrast and diuretics) over the first 48 hours compared to retrospective patients with NC>2.0 (n=12)(p<0.01).

Conclusion


Real-time NC measurement decreases nephrotoxin exposure in at risk patients, increases nephrology-based care and improves ICU patient outcomes.

TIMP2*IGFBP7 Outcomes
Variable (either median(IQR) or n(%))Retrospective Cohort (n=70)Prospective Cohort (n=60)p-value
Baseline Serum Creatinine (mg/dl)1.0 (0.7 - 1.4)1.0 (0.7 - 1.3)0.93
Serum Creatinine on Day of NC Measurement1.1 (0.7 - 1.7)1.4 (1.0 - 2.1)0.012
Nephrocheck value0.33 (0.1 - 1.6)0.74 (0.24 - 2.3)0.06
Reached Stage 2 or 3 AKI18 (24%)17 (28%)0.72
Inpatient Mortality16 (23%)7 (11%)0.08
Nephrology Consult within 24 hour of NC measurement4 (5.7%)11 (18%)0.03